CYP1A1 and breast carcinoma: Thus, metformin decreases CYP1A1 and CYP1B1 expression in breast cancer cells by suppressing the AhR signaling pathway and may act as a potential chemopreventive agent against CYP1B1- and CYP1A1-mediated carcinogenesis and cancer progression [237].